With the announcement of the financial reports of each company, the top 10 global drug sales in 2021 will be released

With the announcement of the financial reports of each company, the top 10 global drug sales in 2021 will be released
.
From the indications, the TOP10 products include 3 COVID-19 products, 3 anti-tumor drugs, 2 autoimmune disease drugs, 1 anticoagulant drug and 1 ophthalmic disease drug
.
From the perspective of drug types, 4 monoclonal antibodies, 3 chemical drugs, 2 vaccines, and 1 antibody fusion protein
.

Compared with the top 10 products in global drug sales in 2020, the order of the other 6 products has not changed
, except for the three dark horses spawned by the new crown epidemic and BMS's Eliquis.
Compared with sales data in 2020, only Humira and Eliquis sales declined
.

In addition, compared with the market volume of TOP10 products in 2020, the market volume of TOP10 products in 2021 can be described as a new high, with sales of 7 products exceeding 10 billion US dollars, of which 1 product sales exceeded 20 billion US dollars and 30 billion US dollars
, respectively.

TOP1 Comirnaty

Comirnaty is an mRNA vaccine jointly developed by Pfizer and BioNTech based on BioNTech's proprietary mRNA technology, which was first authorized by the European Union and the US FDA Emergency Use Authorization (EUA) to prevent COVID-19 infection
in people aged 16 years and older in December 2020.
In August 2021, the vaccine was approved by the FDA as a 2-dose immunization program for immunization of people aged 16 years and older to prevent COVID-19
.
In addition, the vaccine also receives multiple EUAs: (1)2-shot immunization programs for population immunization of adolescents aged 12-15 years to prevent COVID-19; (2) For people aged 12 and above with immunocompromised population, provide the third dose of immunization
.
(3) As a single-dose booster for people aged 16 and over who have completed the Comirnaty 2-dose immunization program, or for people aged 18 and over who have completed another different COVID-19 vaccine immunization program
.

Comirnaty can be described as the peak of its debut, catching up with Humira
, the medicine king who has won the top spot for many years.

TOP2 Humira

Humira is a blockbuster product in the field of autoimmune diseases, and the approved indications include moderate to severe rheumatoid arthritis (adults), moderate to severe polyarticular juvenile idiopathic arthritis (children, ≥ 2 years old), psoriatic arthritis (adults), ankylosing spondylitis (adults), moderate to severe purulent sweaty adenitis (≥ 12-year-old people), moderate to severe Crohn's disease (adults, ≥ children 6 years old), moderate to severe ulcerative colitis (adults, ≥ 5-year-old children), moderate to severe chronic plaque psoriasis (adults), Noninfectious uveitis, posterior uveitis or panuveitis (adults, ≥ children 2 years of age), etc
.

However, due to the impact of biosimilars and other products, Humira's global sales fell in the first year, but it is still in the ranks
of $20 billion.

TOP3 Spikevax

Spikevax (mRNA-1273) is a COVID-19 vaccine that encodes for the new coronavirus spike protein using mRNA, obtained the FDA's EUA in December 2020 to prevent COVID-19 in individuals over the age of 18, in addition to being authorized by the FDA to use as a single dose booster injection after completing other authorized or approved COVID-19 vaccine master immunizations, and officially approved by the FDA in January this year to prevent COVID-19 infection in people over the age of 18
。

Spikevax is the second mRNA vaccine officially approved by the FDA after Pfizer/BioNTech Comirnaty, and the first product
officially approved by the FDA at Moderna.
Currently, Spikevax has been approved by regulatory authorities in more than 70 countries and will sell approximately 810 million doses
worldwide in 2021.

TOP4 Keytruda

Keytruda is the world's best-selling PD-1 monoclonal antibody, and it is also one of the most widely approved indications covering tumor species, and in 2021 the drug has received multiple regulatory approvals, such as adjuvant therapy for renal cell carcinoma (RCC) with a moderate or high risk of recurrence after nephrectomy (surgical removal of the kidney) or nephrectomy and metastatic lesions.
First-line treatment with platinum-based chemotherapy (plus or without bevacizumab) has been confirmed by FDA-approved tests for persistent, recurrent, or metastatic cervical cancer
expressing PD-L1 (with a positive score [CPS]≥1).
In addition, the drug has been developed in conjunction with many other types of drugs for the treatment of tumors
.
In 2021, Keytruda sales continued to grow to $17.
186 billion
.

TOP5 Eylea

Eleea, a novel VEGF inhibitor for intravitreal injection jointly developed by Regeneration Element and Bayer, is a recombinant fusion protein that fuses the extracellular region of human vascular endothelial cell growth factor (VEFG) receptors 1 and 2 with crystallizable fragments of human immunoglobulin G1, and has been approved worldwide for multiple indications, such as diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), retinal vein occlusion (RVO, These include BRVO and CRVO), as well as pathological myopic choroidal neovascularization (myopic CNV) caused by visual impairment
.

For now, Eylea has strong competitors such as Roche's Vabysmo (faricimab-svoa
).
The drug's active drugfaricimab, the first bispecific antibody specifically designed for the eye to function by targeting angiopoietin-2 (Ang-2) and angioendothelial growth factor A (VEGF-A), was approved by the FDA in January this year for the treatment of neovascular, or "wet" age-related macular degeneration (nAMD or wet AMD) and diabetic macular edema (DME
).
However, Renewant is developing a higher dose of Eylea, which can be used every four months to cope with the impact
of new products and bioanas.

TOP6 Revlimid

Revlimid is a heavy immunomodulator obtained by BMS after the acquisition of Xinji, its active pharmaceutical ingredient lenalidomide (lenalidomide) is a new generation of derivatives of thalidomide, non-teratogenic toxicity, 100 times stronger than thalidomide, with immunomodulatory, anti-angiogenesis and anti-tumor properties, has been approved for a variety of indications, such as multiple myeloma (MM), myelodysplastic syndrome (MDS), mantular cell lymphoma (MCL), follicular lymphoma (FL) , marginal lymphoma (MZL
).

Revlimid sales continued to grow
steadily in 2021.
However, chemical drugs are significantly affected by generic drugs, it is reported that Novartis' generic drug company Sandoz has launched Revlimid generic drugs in 19 countries in Europe, and German generic drug manufacturer Stada Arzneimittel has also launched Revlimid generic drugs
in Europe.
BMS expects Revlimid's global sales to fall to between
$9.
5-10 billion in 2022.

TOP7 Eliquis

Elizis is an oral anticoagulant discovered by BMS, and in 2007 Pfizer and BMS reached a collaboration
on the development and commercialization of the drug worldwide.
In May 2011 and December 2012, the drug was approved for marketing in the European Union and the United States, and has now grown into a star product
of BMS and Pfizer.
The drug also faced generic shocks, but the BMS/Pfizer alliance lawsuit won last September, and Eliquis's substance ingredient (COM) patents (US 6,967,208) and formulation patents (US 9.
326,945) were found valid by the U.
S.
Court of Appeals for the Federal Circuit (CAFC), and generic drug manufacturers could launch Eliquis generic drugs
as early as April 1, 2028.
However, due to many factors, Eliquis sales in 2021 have declined
significantly.

TOP8 Imbruvica

Imbruvica is the world's first marketed BTK inhibitor, jointly developed and commercialized by Johnson & Johnson and AbbVie, approved as early as November 2013, and has received 11 FDA approvals in 5 B-cell blood cancers and 6 diseases of chronic graft-versus-host disease (cGVHD): chronic lymphocytic leukemia (CLL) with or without 17p deletion (del17p), Small lymphocyte lymphoma (SLL) with or without 17p deletion mutation (del17p), Waldenstrom macroglobulinemia (WM), previously treated mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) requiring systematic therapy and receiving at least one anti-CD20 therapy, chronic graft-versus-host disease (cGVHD)
that has failed to treat one or more systems therapy.

In 2021, Imbruvica sales grew to $9.
777 billion
.
However, Imbruvica faces fierce competition, and a number of BTK inhibitors have been approved, such as Acerta Pharma's Acalabrutinib, BeiGene's zebutinib, Ono's Tirabrutinib, and Nordg's obrotinib
.

TOP9 REGEN-COV/Ronapreve

REGEN-COV/Ronapreve is an antibody cocktail therapy invented by Regenerative and developed in collaboration with Roche, which is primarily responsible for the development and supply
outside the United States.
The therapy consists of two monoclonal antibodies, casirivimab and imdevimab, which target 2 independent, non-overlapping sites in the receptor-binding region of the acanthosine protein (S protein) of the novel coronavirus (SARS-CoV-2), which have a synergistic effect to reduce the risk of viral mutation escape and protect the population from viral variants
mutated by S protein 。 In November 2020, the therapy was awarded the FDA EUA for the treatment of children and adults who have recently been diagnosed with mild to moderate COVID-19 in children and adults who
have a positive direct test for novel coronavirus (SARS-CoV-2) and are at high risk of developing severe COVID-19 and/or hospitalization, ≥ age ≥ 12 years, and weighing 40 kg 。 In July 2021, the therapy was updated by the FDA to provide post-exposure prophylaxis for people at high risk of developing severe COVID-19, becoming the first COVID-19 antibody therapy
in the United States that can be used for both treatment and post-exposure prophylaxis.
In addition, the therapy is used to treat non-hospitalized patients with COVID-19, as well as BLAs for the prevention of COVID-19 in certain individuals are under priority review in the United States with a PDUFA date of April 13, 2022
.

TOP10 Stelara

Stelara is an IL-12 and IL-23 antagonist developed by Johnson & Johnson's Janssen that has been approved worldwide for the treatment of a variety of autoimmune diseases
such as plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and more.
Stelara's post-IPO sales have climbed year by year, exceeding $5 billion for the first time in 2018 and entering the $9 billion ranks
in 2021.
The autoimmune disease market is also a hot market for pharmaceutical companies to chase, and new products continue to be launched, such as U-Ship's Bimzelx (bimekizumab), and Stella will also face more fierce competitors in the
future.